Cellromax Science Co Ltd

Cellromax maintains a strong liquidity position with a current ratio of 5.2, indicating ample short-term assets to cover liabilities. The company's price-to-book ratio of 1.24 and price-to-tangible-book ratio of 1.24 suggest a market valuation in line with its equity base. With a low debt-to-equity ratio of 0.01, the firm is largely equity-funded, reducing financial leverage risk [doc:HA-latest]. Profitability metrics show a return on equity (ROE) of 6.32% and a return on assets (ROA) of 5.83%, both below the typical thresholds for high-performing retailers. The operating margin of 12.7% (calculated from operating income of 2.81 billion KRW on revenue of 22.18 billion KRW) is in line with the industry's median for specialty retailers, but the net margin of 13.4% (2.97 billion KRW net income) suggests efficient cost control [doc:HA-latest]. The company's revenue is concentrated in a single business segment, health and beauty products, with no disclosed geographic diversification. This concentration increases exposure to demand shifts in the Korean domestic market, where the company operates primarily [doc:HA-latest]. Outlook data indicates a projected 4.5% revenue growth in the current fiscal year and 3.2% in the next, driven by continued demand for health and functional food products. Historical revenue growth has averaged 2.1% annually over the past three years, suggesting a stable but modest growth trajectory [doc:HA-latest]. Risk assessment highlights low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued new shares in the past 12 months, and no dilution sources were identified in recent filings. The absence of long-term debt (477.8 million KRW) further reduces refinancing risk [doc:HA-latest]. Recent filings and transcripts show no material events affecting operations or strategy. The company's 10-K filing for the latest fiscal year reaffirms its focus on expanding its health food product line and maintaining brand loyalty through the 'Cellromax' portfolio [doc:HA-latest].